Lei Zhang

机构：Shanxi Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Institute of Hematology & Blood Diseases Hospital, First Affiliated Hospital of Zhengzhou University, Shanxi Provincial People’s Hospital · ORCID：0000-0002-5768-4840

发表论文 105 篇 · 总被引 1708 次 · h-index 23

代表论文

• A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera (2023 · Experimental Hematology and Oncology · 被引 34)
• IL-24 improves efficacy of CAR-T cell therapy by targeting stemness of tumor cells (2024 · British Journal of Cancer · 被引 27)
• Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma (2023 · Cancer Medicine · 被引 10)
• Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study (2025 · The Lancet Haematology · 被引 9)
• M6A modification-mediated LIMA1 promotes the progression of hepatocellular carcinoma through the wnt-βcatenin/Hippo pathway (2024 · Cell Biology and Toxicology · 被引 9)
• A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study (2023 · Blood · 被引 6)